|
| 35114411 | Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis. | Transplant Cell Ther | 2022 |
| 35773050 | Regulatory Aspects of Gene Therapy: The Regulatory Life Cycle. | Hematol Oncol Clin North Am | 2022 |
| 35747850 | Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. | Hemasphere | 2022 |
| 35114411 | Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis. | Transplant Cell Ther | 2022 |
| 35773050 | Regulatory Aspects of Gene Therapy: The Regulatory Life Cycle. | Hematol Oncol Clin North Am | 2022 |
| 35747850 | Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. | Hemasphere | 2022 |
| 32976576 | A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. | Blood | 2021 |
| 33965189 | Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency. | Transplant Cell Ther | 2021 |
| 33309500 | Clinical Competence Assessed Using Simulation: Development of a Standardized Tool to Assess Nutrition-Focused Physical Exam Skill Competence for Registered Dietitian Nutritionists. | J Nutr Educ Behav | 2021 |
| 32976576 | A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. | Blood | 2021 |
| 33965189 | Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency. | Transplant Cell Ther | 2021 |
| 33309500 | Clinical Competence Assessed Using Simulation: Development of a Standardized Tool to Assess Nutrition-Focused Physical Exam Skill Competence for Registered Dietitian Nutritionists. | J Nutr Educ Behav | 2021 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32105293 | Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. | JAMA Oncol | 2020 |
| 31811481 | Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate. | Support Care Cancer | 2020 |
| 33307615 | Increased competency of registered dietitian nutritionists in physical examination skills after simulation-based education in the United States. | J Educ Eval Health Prof | 2020 |
| 31811481 | Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate. | Support Care Cancer | 2020 |
| 32105293 | Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. | JAMA Oncol | 2020 |
| 33307615 | Increased competency of registered dietitian nutritionists in physical examination skills after simulation-based education in the United States. | J Educ Eval Health Prof | 2020 |
| 30089900 | Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. | Bone Marrow Transplant | 2019 |
| 30089900 | Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. | Bone Marrow Transplant | 2019 |
| 29412158 | Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. | Biol Blood Marrow Transplant | 2018 |
| 29412158 | Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. | Biol Blood Marrow Transplant | 2018 |
| 29496562 | Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. | Biol Blood Marrow Transplant | 2018 |
| 29496562 | Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. | Biol Blood Marrow Transplant | 2018 |
| 28797782 | Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. | Biol Blood Marrow Transplant | 2017 |
| 28825694 | Monozygotic twins with GATA2 deficiency: same haploidentical-related donor, different severity of GvHD. | Bone Marrow Transplant | 2017 |
| 28797782 | Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. | Biol Blood Marrow Transplant | 2017 |
| 30358951 | The power of the first call: What you don't know can hurt you. | MGMA Connex | 2017 |
| 30358951 | The power of the first call: What you don't know can hurt you. | MGMA Connex | 2017 |
| 28825694 | Monozygotic twins with GATA2 deficiency: same haploidentical-related donor, different severity of GvHD. | Bone Marrow Transplant | 2017 |
| 26823601 | Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. | Clin Cancer Res | 2016 |
| 26828906 | Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD. | Bone Marrow Transplant | 2016 |
| 26823601 | Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. | Clin Cancer Res | 2016 |
| 26534966 | Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. | Clin Cancer Res | 2016 |
| 27694491 | Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. | J Immunol | 2016 |
| 26534966 | Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. | Clin Cancer Res | 2016 |
| 27694491 | Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. | J Immunol | 2016 |
| 26828906 | Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD. | Bone Marrow Transplant | 2016 |
| 25363867 | Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. | Am J Hematol | 2015 |
| 25452614 | Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. | Blood | 2015 |
| 25363867 | Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. | Am J Hematol | 2015 |
| 25740857 | Oral disease profiles in chronic graft versus host disease. | J Dent Res | 2015 |
| 25771402 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. | Biol Blood Marrow Transplant | 2015 |
| 25207994 | Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. | JAMA Dermatol | 2015 |
| 25771402 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. | Biol Blood Marrow Transplant | 2015 |
| 25740857 | Oral disease profiles in chronic graft versus host disease. | J Dent Res | 2015 |
| 25452614 | Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. | Blood | 2015 |
| 25207994 | Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. | JAMA Dermatol | 2015 |